Rein Therapeutics Inc. (RNTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Rein Therapeutics Inc.

    NASDAQ: RNTX · Real-Time Price · USD
    1.18
    -0.01 (-0.84%)
    At close: Sep 11, 2025, 1:30 PM

    Rein Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 63K n/a n/a n/a
    Gross Profit
    		 -63K n/a n/a n/a
    Operating Income
    		 -65.11M -16.28K -27.65K -26.61K
    Interest Income
    		 400K n/a n/a n/a
    Pretax Income
    		 -64.31M -15.73K -27.33K -26.16K
    Net Income
    		 -62.88M -15.73K -27.33K -26.16K
    Selling & General & Admin
    		 13.86M 11.36K 9.68K 9.6K
    Research & Development
    		 14.25M 3.99K 17.97K 17.01K
    Other Expenses
    		 -63K 928.00 n/a n/a
    Operating Expenses
    		 28.05M 16.28K 27.65K 26.61K
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 65.11M 16.28K 27.65K 26.61K
    Income Tax Expense
    		 -1.54M n/a n/a n/a
    Shares Outstanding (Basic)
    		 17.94K 4.6K 4.54K 4.44K
    Shares Outstanding (Diluted)
    		 17.94K 4.6K 4.54K 4.44K
    EPS (Basic)
    		 -3.51 -3.42 -6.02 -5.89
    EPS (Diluted)
    		 -3.51 -3.42 -6.02 -5.89
    EBITDA
    		 -28.05M -15.23K -27.48K -26.48K
    EBIT
    		 -28.11M -15.35K -27.65K -26.61K
    Depreciation & Amortization
    		 63K 119.00 169.00 121.00

    Add to Watchlist